Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected south African patients

被引:44
作者
Selabe, S. Gloria
Lukhwareni, Azwidowi
Song, Ernest
Leeuw, Yeegan G. M.
Burnett, Rosemary J.
Mphahlele, M. Jeffrey
机构
[1] Univ Limpopo, Dept Virol, HIV & Hepatitis Res Unit, Pretoria, South Africa
[2] Johannesburg Hosp, Hepatol Div, Dept Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Margarita Hlth Ctr, Pretoria, South Africa
关键词
lamivudine-resistant HBV strains; hepatitis B virus; human immunodeficiency virus; HBV-HIV coinfection; sub-Saharan Africa;
D O I
10.1002/jmv.20974
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This was an exploratory study to investigate larnivudine-resistant hepatitis 13 virus (HBV) strains in selected lamivudine-naive HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients. Thirty-five lamivudine-naive HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HlV co-infected patients. The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg-positive) patients. HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL). Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor((R)) test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients. To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-naive HBV-HIV co-infected patients. The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and < 200 to 4.40 x 10(3) copies/ml, respectively. It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
引用
收藏
页码:1650 / 1654
页数:5
相关论文
共 50 条
  • [41] Comparative analysis of HBV basic core promoter/pre-core gene mutations and viral quasispecies diversity in HIV/HBV co-infected and HBV mono-infected patients
    Deng, Haohui
    Gao, Hongbo
    Liu, Yu
    Xu, Ying
    Yang, Juncheng
    Zhao, Miaoxian
    Liu, Huiyuan
    Wang, Zhanhui
    ACTA VIROLOGICA, 2022, 66 (01) : 18 - 26
  • [42] Epidemiology and Challenges of HBV/HIV Co-Infection Amongst HIV-Infected Patients in Endemic Areas: Review
    Weldemhret, Letebrhan
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2021, 13 : 485 - 490
  • [43] Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals
    Giron, Leila B.
    Azzoni, Livio
    Yin, Xiangfan
    Lynn, Kenneth M.
    Ross, Brian N.
    Fair, Matthew
    Damra, Mohammad
    Sciorillo, Amanda C.
    Liu, Qin
    Jacobson, Jeffrey M.
    Mounzer, Karam
    Kostman, Jay R.
    Abdel-Mohsen, Mohamed
    Montaner, Luis J.
    Papasavvas, Emmanouil
    AIDS, 2020, 34 (10) : 1461 - 1466
  • [44] Frequent Detection of Hepatitis B Virus Variants Associated With Lamivudine Resistance in Treated South African Patients Infected Chronically With Different HBV Genotypes
    Selabe, S. Gloria
    Song, Ernest
    Burnett, Rosemary J.
    Mphahlele, M. Jeffrey
    JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (06) : 996 - 1001
  • [45] Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV
    Boyd, Anders
    Maylin, Sarah
    Gozlan, Joel
    Delaugerre, Constance
    Simon, Francois
    Girard, Pierre-Marie
    Lacombe, Karine
    LIVER INTERNATIONAL, 2015, 35 (03) : 795 - 804
  • [46] Demographic and clinical factors associated with immune reconstitution in HIV/HBV co-infected and HIV mono-infected patients: a retrospective cohort study
    Jiang, T. Y.
    Hou, J. H.
    Su, B.
    Zhang, T.
    Yang, Y.
    Liu, Z. Y.
    Wang, W.
    Guo, C. P.
    Dai, L. L.
    Sun, L. J.
    Wu, H.
    HIV MEDICINE, 2020, 21 (11) : 722 - 728
  • [47] Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients
    Sherman, Kenneth E.
    Guedj, Jeremie
    Shata, Mohamed Tarek
    Blackard, Jason T.
    Rouster, Susan D.
    Castro, Mario
    Feinberg, Judith
    Sterling, Richard K.
    Goodman, Zachary
    Aronow, Bruce J.
    Perelson, Alan S.
    SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (246)
  • [48] HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome
    Su, Shu
    Fairley, Christopher K.
    Sasadeusz, Joe
    He, Jianmei
    Wei, Xiuqing
    Zeng, Huan
    Jing, Jun
    Mao, Limin
    Chen, Xi
    Zhang, Lei
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (03) : 518 - 525
  • [49] Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review
    Ashwani K Singal
    Bhupinderjit S Anand
    World Journal of Gastroenterology, 2009, 15 (30) : 3713 - 3724
  • [50] Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review
    Singal, Ashwani K.
    Anand, Bhupinderjit S.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (30) : 3713 - 3724